CooperVision has announced its MiSight 1 day contact lenses are now available in higher prescriptions, making myopia control accessible to more children than was previously possible.
The expanded range, covering -0.25D to -10.00D (0.50D steps after -6.00D), means that MiSight 1 day covers 99.97% of prescriptions for Asian children – and likewise for Caucasian children – who have myopia and less than 1D of astigmatism.
CooperVision said the diopter extension for its innovative, specially designed lens will allow even more children to benefit from myopia management.
According to the company, MiSight 1 day contact lenses are supported by the longest-running soft contact lens study among children.
“The clinical trial has proven that MiSight 1 day works for nearly all children with myopia, cuts myopia progression by half, works at any age a child starts treatment (8+), works for as long as the child wears them, and that myopia control benefits from MiSight 1 day are retained after treatment,” the company said.
It said that with myopia on the rise globally, an increasing number of children may require the higher prescriptions that MiSight 1 day lenses will offer.
CooperVision director of global professional affairs, myopia management, Ms Elizabeth Lumb, said while early treatment is best, it’s never too late to start.
“Every diopter matters, particularly for children whose myopia progression may have already placed them at a higher risk for conditions such as myopic maculopathy and glaucoma,” she said.
“Even older children starting with MiSight 1 day have seen their myopia progression cut by half.”
As a global leader in myopia control and management for children, CooperVision believes that options must be available for as many children as possible.
“With MiSight 1 day’s range extension, eyecare professionals in Australia and New Zealand and in more than 30 other countries can have an even greater impact,” the company said.
Research has shown that children aged 8-15 with myopia fitted with MiSight 1 day contact lenses continued to experience slowed myopia progression as long as they remained in treatment.
Twelve months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following three or six-years of MiSight 1 day wear (on average, for children aged 8-15 at start of wear). Instead, eye growth reverted to expected, age average myopic progression rates.